Nova Patents
AT417609T

Controlled release arginine formulations

Abstract

The sustained release product of L* arginine combined with the active substance which promotes the biotransformation of independence or L* arginine to NO is written in this book. Fig. 1A shows the schematic view of L* arginine dependence to propose and a non-dependence course.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

87 members in 12 offices

This recordMember, by publication datePriority claim2 more offices are in the list below

Priority claims1

Priority claims
DocumentOfficeKindDate
60559900United States of AmericaA

Members87

Family members, oldest first
DocumentOfficeKind
CA2201784A1CanadaA1
WO9610910A1World Intellectual Property Organization (WIPO)A1
AU3889695AAustraliaA
US5543430AUnited States of AmericaA
EP0784429A1European Patent Office (EPO)A1
MX9702527AMexicoA
US5767160AUnited States of AmericaA
JPH10507443AJapanA
CA2286671A1CanadaA1
WO9844893A2World Intellectual Property Organization (WIPO)A2
AU7115098AAustraliaA
WO9844893A3World Intellectual Property Organization (WIPO)A3
AU705002B2AustraliaB2
US5968983AUnited States of AmericaA
CA2358212A1CanadaA1
WO0040086A1World Intellectual Property Organization (WIPO)A1
AU2603400AAustraliaA
EP1022945A2European Patent Office (EPO)A2
CA2369772A1CanadaA1
WO0062614A1World Intellectual Property Organization (WIPO)A1
AU4248100AAustraliaA
EP0784429A4European Patent Office (EPO)A4
CA2388530A1CanadaA1
WO0128499A2World Intellectual Property Organization (WIPO)A2
AU2116201AAustraliaA
US6239172B1United States of AmericaB1
WO0128499A3World Intellectual Property Organization (WIPO)A3
EP1139753A1European Patent Office (EPO)A1
JP2001523224AJapanA
CA2413816A1CanadaA1
WO0200212A1World Intellectual Property Organization (WIPO)A1
AU7170001AAustraliaA
EP1178727A1European Patent Office (EPO)A1
AU744813B2AustraliaB2
US6425881B1United States of AmericaB1
EP1225885A2European Patent Office (EPO)A2
JP2002534360AJapanA
US6465516B1United States of AmericaB1
DE10209963A1GermanyA1
US2002151369A1United States of AmericaA1
JP2002310179AJapanA
US6540616B2United States of AmericaB2
EP1022945A4European Patent Office (EPO)A4
US2003114515A1United States of AmericaA1
MXPA01006926AMexicoA
EP1377284A1European Patent Office (EPO)A1
US2004006140A1United States of AmericaA1
EP1225885A4European Patent Office (EPO)A4
JP2004513877AJapanA
MXPA02004021AMexicoA
CA2201784CCanadaC
MXPA01010460AMexicoA
MXPA03000194AMexicoA
US2004186164A1United States of AmericaA1
US2004204484A1United States of AmericaA1
US2004242682A1United States of AmericaA1
EP0784429B1European Patent Office (EPO)B1
EP1139753A4European Patent Office (EPO)A4
AT287212TAustriaT
ATE287212T1AustriaT1
DE69533940D1GermanyD1
US2005085548A1United States of AmericaA1
DK0784429T3DenmarkT3
PT784429EPortugalE
EP1552745A1European Patent Office (EPO)A1
ES2236716T3SpainT3
DE69533940T2GermanyT2
EP1377284A4European Patent Office (EPO)A4
EP1178727A4European Patent Office (EPO)A4
EP1139753B1European Patent Office (EPO)B1
AT367087TAustriaT
ATE367087T1AustriaT1
DE60035574D1GermanyD1
JP3989260B2JapanB2
EP1552745B1European Patent Office (EPO)B1
AT388700TAustriaT
ATE388700T1AustriaT1
DE69535734D1GermanyD1
US7381731B2United States of AmericaB2
EP1377284B1European Patent Office (EPO)B1
AT417609TThis recordAustriaT
ATE417609T1AustriaT1
DE60137082D1GermanyD1
CA2286671CCanadaC
US2011196039A9United States of AmericaA9
US2011212174A1United States of AmericaA1
DE10209963B4GermanyB4